Results 31 to 40 of about 39,201 (181)

Cardiovascular events and safety outcomes associated with remdesivir using a World Health Organization international pharmacovigilance database

Clinical and Translational Science, 2022
On October 2020, the US Food and Drug Administration (FDA) approved remdesivir as the first drug for the treatment of coronavirus disease 2019 (COVID‐19), increasing remdesivir prescriptions worldwide.
Se Yong Jung, Min Seo Kim, Han Li, Keum Hwa Lee, Ai Koyanagi, Marco Solmi, Andreas Kronbichler, Elena Dragioti, Kalthoum Tizaoui, Sarah Cargnin, Salvatore Terrazzino, Sung Hwi Hong, Ramy Abou Ghayda, Nam Kyun Kim, Seo Kyoung Chung, Louis Jacob, Joe‐Elie Salem, Dong Keon Yon, Seung Won Lee, Karel Kostev, Ah Young Kim, Jo Won Jung, Jae Young Choi, Jin Soo Shin, Soon‐Jung Park, Seong Woo Choi, Kiwon Ban, Sung‐Hwan Moon, Yun Young Go, Jae Il Shin, Lee Smith   +30 more
doaj   +1 more source

Effect of remdesivir on mortality and the need for mechanical ventilation among hospitalized patients with COVID-19: real-world data from a resource-limited country

International Journal of Infectious Diseases, 2023
Objectives: Georgia introduced remdesivir for the treatment of COVID-19 in December 2020. We evaluated the real-world effect of remdesivir on mortality and the need for mechanical ventilation among inpatients with COVID-19.
Revaz Metchurtchlishvili, Nikoloz Chkhartishvili, Akaki Abutidze, Marina Endeladze, Marine Ezugbaia, Ana Bakradze, Tengiz Tsertsvadze   +6 more
doaj   +1 more source

Viruses by Remdesivir

, 2021
Remdesivir is an antiviral drug initially designed against the Ebola virus. The results obtained with it both in biochemical studies in vitro and in cell line assays in vivo were very promising, but it proved ineffective in clinical trials.
Lisi, George P., Wang, Jimin, Reiss, Krystle, Yuanjun Shi, Batista, Victor S., Victor S. Batista, Shi, Yuanjun, Elias Lolis, George P. Lisi, Lolis, Elias, Jimin Wang, Krystle Reiss   +11 more
core   +1 more source

Summary of remdesivir allocation strategies.

, 2021
Summary of remdesivir allocation strategies.
Karishma Desai (7516163), Ilene Harris (4110925), Sanchari Ghosh (11576840), Sabeen Ali (11576843), Zippora Kiptanui (8787014)   +4 more
core   +1 more source

Remdesivir (GS-5734) Impedes Enterovirus Replication Through Viral RNA Synthesis Inhibition

Frontiers in Microbiology, 2020
Human enteroviruses are responsible for diverse diseases, from mild respiratory symptoms to fatal neurological complications. Currently, no registered antivirals have been approved for clinical therapy.
Wei Ye, Min Yao, Yangchao Dong, Chuantao Ye, Dan Wang, He Liu, Hongwei Ma, Hui Zhang, Libin Qi, Yuewu Yang, Yuan Wang, Liang Zhang, Linfeng Cheng, Xin Lv, Zhikai Xu, Yingfeng Lei, Fanglin Zhang   +16 more
doaj   +1 more source

Hemoadsorption eliminates remdesivir from the circulation: Implications for the treatment of COVID‐19

Pharmacology Research & Perspectives, 2021
Both antiviral treatment with remdesivir and hemoadsorption using a CytoSorb® adsorption device are applied in the treatment of severe COVID‐19. The CytoSorb® adsorber consists of porous polymer beads that adsorb a broad range of molecules, including ...
Paul Biever, Dawid L. Staudacher, Michaela J. Sommer, Hannah Triebel, Merja A. Neukamm, Christoph Bode, Alexander Supady, Achim Lother   +7 more
doaj   +1 more source

Prominent bradycardia in a COVID-19 patient receiving Remdesivir: a case report

Qanun Medika: Jurnal Kedokteran Fakultas Kedokteran Universitas Muhammadiyah Surabaya, 2022
Remdesivir is a commonly used antiviral drug to treat COVID-19. Remdesivir has some side effects; however, whether it has any effect on cardiac is rarely reported.
Sidhi Laksono Purwowiyoto, Grace Trifena Hosea   +1 more
doaj   +1 more source

Activation of the urotensin-II receptor by remdesivir induces cardiomyocyte dysfunction

Communications Biology, 2023
Remdesivir is an antiviral drug used for COVID-19 treatment worldwide. Cardiovascular side effects have been associated with remdesivir; however, the underlying molecular mechanism remains unknown.
Akiko Ogawa, Seiya Ohira, Yuri Kato, Tatsuya Ikuta, Shota Yanagida, Xinya Mi, Yukina Ishii, Yasunari Kanda, Motohiro Nishida, Asuka Inoue, Fan-Yan Wei   +10 more
doaj   +1 more source

Precipitating factors of bradycardia after remdesivir administration: ICU admission and cutoff value for declining heart rate

Journal of Microbiology, Immunology and Infection, 2023
Background: Despite increasing concerns about the association between remdesivir and bradycardia in severe coronavirus disease 2019 (COVID-19) patients receiving remdesivir, information on its clinical course and precipitating factors is limited. Our aim
Yan-Zuo Chen, Ming-Shen Lin, Yi-Ping Lin, Yi-Zhan Liu, Chia-Jui Yang   +4 more
doaj   +1 more source

Remdesivir: A Review in COVID-19

, 2023
Declarations Funding The preparation of this review was not supported by any external funding. Authorship and Conflict of interest Hannah A. Blair is a salaried employee of Adis International Ltd/Springer Nature and declares no relevant conflicts of ...
Hannah A. Blair (6846307)
core   +1 more source